VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
UVE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
UVEUniversal Insurance Holdings, Inc.
$41.13$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksUVEFinancials

Universal Insurance Holdings, Inc. (UVE) Financials

30Y historyFree accessUpdated daily

Underwriting efficiency has improved significantly, with the combined ratio falling to 81.7% in 2026Q1 from the 104.7% peak observed in 2024Q3, despite a modest revenue contraction of -0.9%.

UVE Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Apr'97Apr'96
Revenue1.6B1.6B1.52B1.39B1.22B1.12B1.07B939.35M823.82M751.92M685.29M546.54M369.28M301.16M269.94M225.86M239.92M210.64M182.67M188.51M65.15M19.66M8M6.48M9.26M13.44M9.15M8.1M8.5M100K400K
Revenue Growth %3.31%4.94%9.27%13.82%8.99%4.58%14.2%14.02%9.56%9.72%25.39%48%22.62%11.57%19.52%-5.86%13.9%15.31%-3.1%189.36%231.34%145.81%23.44%-30.04%-31.08%46.95%12.91%-4.71%8400%-75%-60%
Medical Costs & Claims1.09B985.88M1.32B1.2B1.15B1.01B957.91M780.94M571.78M489.27M427.21M275.96M123.28M108.61M126.19M124.31M113.36M106.13M81.34M59.8M24.94M9.6M2.27M974.49K4.64M000000
Medical Cost Ratio %68.12%61.79%86.86%86.28%94.27%89.62%89.29%83.14%69.41%65.07%62.34%50.49%33.38%36.07%46.75%55.04%47.25%50.39%44.53%31.72%38.28%48.82%28.43%15.04%50.08%0%0%0%0%0%0%
Gross Profit509.71M609.72M199.73M190.94M70M116.48M114.86M158.41M252.03M262.64M258.08M270.59M246M192.54M143.75M101.55M126.57M104.51M101.33M128.71M40.21M10.06M5.72M5.51M4.62M13.44M9.15M8.1M8.5M100K400K
Gross Margin %31.88%38.21%13.14%13.72%5.73%10.38%10.71%16.86%30.59%34.93%37.66%49.51%66.62%63.93%53.25%44.96%52.75%49.61%55.47%68.28%61.72%51.18%71.57%84.96%49.92%100%100%100%100%100%100%
Gross Profit Growth %-205.28%4.6%172.76%-39.9%1.41%-27.5%-37.15%-4.04%1.77%-4.62%9.99%27.76%33.94%41.56%-19.76%21.11%3.14%-21.28%220.13%299.52%75.8%3.98%19.07%-65.59%46.95%12.91%-4.71%8400%-75%-60%
Operating Expenses250.41M366.65M115.11M102.59M97.25M88.07M90.63M94.9M99.16M92.16M95.2M95.56M118.4M91.99M91.19M67.83M64.29M58.35M35.32M39.17M13.49M4.01M5.98M5.79M4.55M8.71M6.47M7.6M7.1M400K1.6M
OpEx / Revenue %15.66%22.98%7.57%7.37%7.95%7.85%8.45%10.1%12.04%12.26%13.89%17.49%32.06%30.54%33.78%30.03%26.8%27.7%19.34%20.78%20.7%20.41%74.82%89.31%49.16%64.82%70.77%93.83%83.53%400%400%
Depreciation & Amortization7.07M7.07M6.12M7.31M7.3M6.91M5.11M4.96M4.82M4.06M3.24M2.03M1.19M1.01M840K639K831K490.06K480.31K371.66K358.41K377.75K390.25K268.95K236.32K157.31K98.45K200K00-300K
Combined Ratio %83.78%84.77%94.44%93.65%102.23%97.47%97.74%93.24%81.44%77.33%76.23%67.98%65.44%66.61%80.53%85.07%74.04%78.08%63.87%52.5%58.98%69.22%103.25%104.34%99.23%64.82%70.77%93.83%83.53%400%400%
Operating Income259.31M243.07M84.61M88.35M-27.25M28.41M24.23M63.52M152.87M170.48M162.88M175.02M127.6M100.56M52.56M33.72M62.28M46.16M66.01M89.55M26.72M6.05M-260.13K-281.53K71.05K4.73M2.67M1.2M2.1M-300K-1.2M
Operating Margin %16.22%15.23%5.56%6.35%-2.23%2.53%2.26%6.76%18.56%22.67%23.77%32.02%34.56%33.39%19.47%14.93%25.96%21.92%36.13%47.5%41.02%30.78%-3.25%-4.34%0.77%35.18%29.23%14.81%24.71%-300%-300%
Operating Income Growth %-187.28%-4.23%424.25%-195.9%17.26%-61.85%-58.45%-10.33%4.67%-6.94%37.16%26.9%91.32%55.88%-45.86%34.91%-30.06%-26.29%235.12%341.57%2426.29%7.6%-496.23%-98.5%76.87%122.79%-42.86%800%75%-20%
EBITDA270.82M250.14M90.73M95.66M-19.95M35.33M29.34M68.47M157.69M174.54M166.13M177.06M128.8M101.57M53.4M34.36M63.11M46.65M66.49M89.92M27.08M6.43M130.11K-12.57K307.37K4.89M2.77M1.4M2.1M-300K-1.5M
EBITDA Margin %16.94%15.68%5.97%6.87%-1.63%3.15%2.73%7.29%19.14%23.21%24.24%32.4%34.88%33.73%19.78%15.21%26.3%22.15%36.4%47.7%41.57%32.7%1.63%-0.19%3.32%36.35%30.31%17.28%24.71%-300%-375%
Interest Expense4.99M4.83M5.77M5.82M5.91M582K95K000000000000000000000000
Non-Operating Income-6.05M-6.42M-5.77M-5.82M-5.91M-582K-95K000000000197000000000000-300K-1.2M
Pretax Income259.31M243.07M84.61M88.35M-27.25M28.41M24.23M63.52M152.87M170.48M162.88M175.02M127.6M100.56M52.56M33.72M62.28M46.16M66.01M89.55M26.72M6.05M-260.13K-281.53K71.05K4.73M2.67M1.2M2.1M-300K-1.2M
Pretax Margin %16.22%15.23%5.56%6.35%-2.23%2.53%2.26%6.76%18.56%22.67%23.77%32.02%34.56%33.39%19.47%14.93%25.96%21.92%36.13%47.5%41.02%30.78%-3.25%-4.34%0.77%35.18%29.23%14.81%24.71%-300%-300%
Income Tax63.5M60.12M25.68M21.53M-4.99M8.01M5.13M17M35.82M63.55M63.47M68.54M54.62M41.58M22.25M13.61M25.29M17.38M25.97M35.55M9.48M-455.15K0000000100K300K
Effective Tax Rate %24.49%24.73%30.35%24.36%18.31%28.18%21.15%26.77%23.43%37.28%38.97%39.16%42.8%41.35%42.33%40.36%40.61%37.64%39.34%39.7%35.47%-7.52%0%0%0%0%0%0%0%-33.33%-25%
Net Income195.8M182.95M58.93M66.82M-22.26M20.41M19.11M46.51M117.05M106.94M99.41M106.48M72.99M58.98M30.31M20.11M36.98M28.79M40.04M54M17.19M6.51M-260.13K-281.53K71.05K-3.04M-1.49M1.2M2.1M-2.4M-1.5M
Net Margin %12.25%11.47%3.88%4.8%-1.82%1.82%1.78%4.95%14.21%14.22%14.51%19.48%19.77%19.58%11.23%8.9%15.41%13.67%21.92%28.65%26.38%33.09%-3.25%-4.34%0.77%-22.61%-16.27%14.81%24.71%-2400%-375%
Net Income Growth %193.51%210.47%-11.81%400.23%-209.07%6.82%-58.93%-60.26%9.46%7.57%-6.64%45.89%23.76%94.57%50.74%-45.63%28.47%-28.1%-25.86%214.21%164.15%2601.26%7.6%-496.23%102.34%-104.23%-224.01%-42.86%187.5%-60%-15.38%
EPS (Diluted)6.806.322.012.22-0.720.650.601.363.272.992.792.972.081.560.750.500.910.710.991.310.440.19-0.01-0.010.01-0.21-0.100.080.13-0.11-0.07
EPS Growth %196.07%214.43%-9.46%408.33%-210.77%8.33%-55.88%-58.41%9.36%7.17%-6.06%42.79%33.33%108%50%-45.05%28.17%-28.28%-24.43%197.73%131.58%-27.12%-104.19%-110%-232.45%-41.92%218.18%-61.53%-15.42%
EPS (Basic)-6.562.072.24-0.720.650.601.373.363.072.853.062.171.640.760.510.950.761.071.520.500.20-0.01-0.010.01-0.21-0.100.080.13-0.11-0.07
Diluted Shares Outstanding28.81M28.81M29.27M30.15M30.75M31.31M31.97M34.23M35.79M35.81M35.65M35.88M35.15M37.78M40.62M40.44M40.58M40.47M40.27M41.36M39.08M33.95M30.21M23.78M16.17M14.7M14.79M15.9M16.6M22.04M22.04M

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Florida catastrophe exposure concentration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Underwriting Efficiency Shows Recent Improvement

As reported in recent financial statements, UVE achieved a combined ratio of 78.2% in 2025Q4, marking a significant improvement from the 104.7% peak observed in 2024Q3, suggesting that the company's underwriting discipline is currently benefiting from a more favorable claims environment and reduced litigation pressure.

The volatility in the combined ratio highlights the company's extreme sensitivity to seasonal weather events and the broader Florida legal landscape. While the recent sub-80% combined ratios indicate strong underwriting profitability, investors should monitor whether these levels are sustainable or merely a reflection of a temporary lull in major catastrophe activity.

Premium Growth Normalizing Amid Market Constraints

Based on reported figures, UVE's revenue growth has decelerated to a modest -0.9% in 2026Q1, contrasting with the double-digit growth seen in early 2024, which suggests that the company is prioritizing underwriting profitability and risk management over aggressive top-line expansion in the current hard market cycle.

The shift toward more conservative growth appears to be a strategic response to the rising costs of reinsurance and the need to maintain capital adequacy. This trajectory indicates that management is likely focusing on rate adequacy rather than volume, which may be a prudent approach given the inherent volatility of the Florida residential insurance market.

Legislative Tailwinds Impacting Earnings Volatility

According to recent SEC filings, the transition from a 104.7% combined ratio in 2024Q3 to more stable levels in subsequent quarters suggests that recent Florida tort reforms may be successfully mitigating the litigation-driven loss adjustment expenses that previously pressured the company's bottom line.

The 2024Q3 period serves as a critical inflection point where the impact of prior-year loss development and litigation costs became unsustainable. The subsequent recovery in operating income suggests that the legislative environment may be providing a structural tailwind, though this remains subject to the long-term efficacy of the new legal framework.

Reinsurance Dependency Masks Underlying Risk

While UVE's recent profitability appears robust, the company's heavy reliance on third-party reinsurance, as evidenced by the significant gap between gross and net premiums, warrants further investigation into the potential for future margin compression if global reinsurance treaty pricing continues to harden.

The company's integrated model provides operational control, but the ultimate profitability remains tethered to the availability and cost of external risk transfer. Investors should be cautious, as any systemic failure or significant price hike in the reinsurance market could rapidly erode the current underwriting margins.

UVE — Frequently Asked Questions

Quick answers to the most common questions about buying UVE stock.

What was Universal Insurance Holdings, Inc.'s (UVE) revenue in 2025?

For fiscal year 2025, Universal Insurance Holdings, Inc. (UVE) reported total revenue of $1.60B. This represents a 398799.8% increase compared to $0.4M in 1995.

Is Universal Insurance Holdings, Inc. (UVE) profitable?

Universal Insurance Holdings, Inc. (UVE) is profitable, generating $183.0M in net income for the fiscal year ending 2025 with a net profit margin of 11.5%.

What is Universal Insurance Holdings, Inc.'s operating profit margin?

Universal Insurance Holdings, Inc. (UVE) reported an operating income of $243.1M, resulting in an operating profit margin of 15.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Universal Insurance Holdings, Inc.'s gross profit and gross margin?

Universal Insurance Holdings, Inc. (UVE) generated $609.7M in gross profit for the year, representing a gross profit margin of 38.2%. This demonstrates the company's core pricing power and production efficiency.